<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nur Mursyida Saad</style></author><author><style face="normal" font="default" size="100%">Mahendran Sekar</style></author><author><style face="normal" font="default" size="100%">Siew Hua Gan</style></author><author><style face="normal" font="default" size="100%">Pei Teng Lum</style></author><author><style face="normal" font="default" size="100%">Jaishree Vaijanathappa</style></author><author><style face="normal" font="default" size="100%">Subban Ravi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Resveratrol: Latest Scientific Evidences of its Chemical, Biological Activities and Therapeutic Potentials</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bioavailability</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammatory cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular targets</style></keyword><keyword><style  face="normal" font="default" size="100%">Pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Resveratrol</style></keyword><keyword><style  face="normal" font="default" size="100%">Toxicity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">November 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1779-1791</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Resveratrol is a non-flavonoid polyphenol possesses many biological properties with great potential to develop into various products. In order to cure a wide variety of diseases, resveratrol has attracted a great deal of attention for medicinal purposes.&lt;strong&gt; Objective:&lt;/strong&gt; The present review aimed to provide a comprehensive literature summary of latest scientific evidences on the chemistry, biological properties and therapeutic potentials of resveratrol. &lt;strong&gt;Methods: &lt;/strong&gt;To complete this review, relevant literatures were collected from several scientific databases, including Google Scholar, Pubmed and ScienceDirect, using keywords “source”, “chemistry”, “bioavailability”, “pharmacokinetics”, “isolation”, “anticancer”, “analgesic”, “antiinflammatory”, “antidiabetic”, “nephroprotective activity”, “neuroprotective activity”, “antiobesity”, “cardioprotective effects”, “antioxidant”, “anti-aging” with resveratrol. After a detailed screening process for inclusion and exclusion, the information obtained was summarised.&lt;strong&gt; Results:&lt;/strong&gt; The information on the source, chemistry, bioavailability, biological and therapeutic potentials of resveratrol were tabled. In various pathological conditions, resveratrol can be considered as powerful antioxidants along with multidimensional molecular targets such as NF-ҡB, MAPK, AMPK, SIRT-1, Nrf-2, m-TOR, PI3K/Akt and PPAR-γ signaling pathways. &lt;strong&gt;Conclusion:&lt;/strong&gt; Based on the existing knowledge, we may believe that resveratrol has a significant therapeutic potential for the treatment of various diseases. To accelerate the development and utilization of resveratrol as promising products, in-depth studies should be focused on exploiting its properties and developing phytopharmaceuticals.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6s</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">1779</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Nur Mursyida Saad&lt;sup&gt;1&lt;/sup&gt;, Mahendran Sekar&lt;sup&gt;1,&lt;/sup&gt;*, Siew Hua Gan&lt;sup&gt;2&lt;/sup&gt;, Pei Teng Lum&lt;sup&gt;1&lt;/sup&gt;, Jaishree Vaijanathappa&lt;sup&gt;3&lt;/sup&gt;, Subban Ravi&lt;sup&gt;4 &lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh – 30450, Perak, MALAYSIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Selangor Darul Ehsan, MALAYSIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru – 570015, JSS Academy of Higher Education and Research, Mysuru, Karnataka, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Chemistry, Karpagam Academy of Higher Education, Coimbatore – 640 021, Tamil Nadu, INDIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sayeli Vinaykumar</style></author><author><style face="normal" font="default" size="100%">Urval Pundarik Rathnakar</style></author><author><style face="normal" font="default" size="100%">Ullal Sheetal Dinkar</style></author><author><style face="normal" font="default" size="100%">Kamath Priyanka</style></author><author><style face="normal" font="default" size="100%">Tiwary Gaurav</style></author><author><style face="normal" font="default" size="100%">Shenoy Ashok Kudgi</style></author><author><style face="normal" font="default" size="100%">Revappala Sekhar Nishith</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-Inflammatory agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Bioavailability</style></keyword><keyword><style  face="normal" font="default" size="100%">Curcumin</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Wistar rats.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June/2016</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">380-384</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align:justify&quot;&gt;&lt;strong&gt;Objective&lt;/strong&gt;: To evaluate anti-inflammatory activity of bioenhanced turmeric formulation (BCM-95) compared to commercial Curcumin formulation (Curcuminoids 95%) in Carrageenan-induced acute inflammatory model. &lt;strong&gt;Materials and Methods&lt;/strong&gt;: Thirty six Wistar rats were divided into six groups-Normal control (2 ml of vehicle), Standard control (Indomethacin 10 mg/kg), 2 doses of BCM 95 (10 and 20 mg/kg) and Curcuminoids 95% (10 and 20 mg/kg). Paw volume was measured using a digital plethysmometer. Vehicle or test drugs were given to rats 30 min before carrageenan administration. Baseline paw volume reading (V&lt;sub&gt;0&lt;/sub&gt;) was noted just prior to administration of 0.1 ml of 1% carrageenan to right hind paw of the rat. Test paw volume readings (V&lt;sub&gt;t&lt;/sub&gt;) were measured at 30, 60, 120, 180, 240, 300 and 360 min, after carrageenan injection. Oedema expressed as increased paw volume (v&lt;sub&gt;t&lt;/sub&gt;-v&lt;sub&gt;0&lt;/sub&gt;) was noted and percentage inhibition of oedema was calculated for all treatment groups. &lt;strong&gt;Statistical analysis&lt;/strong&gt;: Difference between groups were analyzed with ANOVA followed by Tukey test. &lt;strong&gt;Results:&lt;/strong&gt; All treatment groups demonstrated significant (p&amp;lt;0.05) anti-inflammatory activity (oedema suppression) compared to normal control&lt;strong&gt;. &lt;/strong&gt;Anti-inflammatory activity of BCM 95 treated groups were comparable to standard control group except at certain time points, whereas the same activity at all-time points with Curcuminoid 95% treated groups were significantly less than standard control group. Percentage inhibition of paw oedema was maximum with standard control group followed by BCM 95 treated groups followed by Curcuminoid 95% treated groups. &lt;strong&gt;Conclusion:&lt;/strong&gt; BCM 95 treated groups showed significant anti-inflammatory activity compared to Curcuminoid 95% treated groups.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">380</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;strong&gt;Sayeli Vinaykumar&lt;sup&gt;1&lt;/sup&gt;, Urval Pundarik Rathnakar&lt;sup&gt;2&lt;/sup&gt;, Ullal Sheetal Dinkar&lt;sup&gt;1&lt;/sup&gt;*, Kamath Priyanka&lt;sup&gt;1&lt;/sup&gt;, Tiwary Gaurav&lt;sup&gt;1&lt;/sup&gt;, Ashok Shenoy Kudgi&lt;sup&gt;1&lt;/sup&gt;, Revappala Sekhar Nishith&lt;sup&gt;3&lt;/sup&gt; &lt;/strong&gt;&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmacology, Kasturba Medical College, Mangaluru, Manipal University, Manipal, INDIA.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Pharmacology, Kanachur Institute of Medical Sciences, Deralakatte, Mangaluru. 575018, INDIA.&lt;/p&gt;

&lt;p style=&quot;text-align: justify;&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Scoop Med Inc, Bengaluru, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>